SE: Keiser Report | R.I.P Exorbitant Privilege? | E1554

Keiser Report via Youtube


Check Keiser Report website for more: http://www.maxkeiser.com/

In this episode of the Keiser Report, Max and Stacy discuss the conspiracy theorists now promising the world will end on the 21st of June. In light of stock market investors going euphoric for bankrupt, soon to be dead companies, could this set a new parabolic rally in motion? In the second half, Max talks to James Turk of Goldmoney.com about the end of the ‘exorbitant privilege.’ Is it here? Yale economist, Stephen Roach, sees the collapse of the dollar, so could hyperinflation happen?

Listen to this episode on Soundcloud: https://soundcloud.com/rttv/sets/keiser-report-1

WATCH all Keiser Report shows here:
http://www.youtube.com/playlist?list=PL768A33676917AE90 (E1-E200)
http://www.youtube.com/playlist?list=PLC3F29DDAA1BABFCF (E201-E400)
http://www.youtube.com/playlist?list=PLPszygYHA9K2ZtV_1KphSugBB7iZqbFyz (E401-E600)
http://www.youtube.com/playlist?list=PLPszygYHA9K1GpAv3ZKpNFoEvKaY2QFH_ (E601-E800)
https://www.youtube.com/playlist?list=PLPszygYHA9K19wt4CP0tUgzIxpJDiQDyl (E801-E1000)
https://www.youtube.com/playlist?list=PLPszygYHA9K302vF9LY8cZJ4_VJB8P347 (E1001 – E1200)
https://www.youtube.com/playlist?list=PLPszygYHA9K3PH1O090X7qlN2_fxziU5M (E1201 – E1400)
https://www.youtube.com/playlist?list=PLPszygYHA9K0lwJo35wu2A0J3RYt-Atla (E1401-Current)

Subscribe to RT! https://www.youtube.com/channel/UCpwvZwUam-URkxB7g4USKpg?sub_confirmation=1

RT LIVE https://www.youtube.com/watch?v=IFAcqaNzNSc

Check out http://rt.com

Like us on Facebook http://www.facebook.com/RTnews
Follow us on VK https://vk.com/rt_international
Follow us on Twitter http://twitter.com/RT_com
Follow us on Instagram http://instagram.com/rt
Follow us on Soundcloud https://soundcloud.com/rttv

#RT (Russia Today) is a global #news network broadcasting from Moscow, London, Paris and Washington studios to over 100 countries. RT is the first news channel to break the 1 billion YouTube views benchmark.

READ ALSO  Pharma industry seizes on pandemic as a shot at redemption